4.7 Article

A nanoreactor boosts chemodynamic therapy and ferroptosis for synergistic cancer therapy using molecular amplifier dihydroartemisinin

Journal

JOURNAL OF NANOBIOTECHNOLOGY
Volume 20, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s12951-022-01455-0

Keywords

Chemodynamic therapy (CDT); Nanoreactor; Dihydroartemisinin (DHA); Nanoscale metal-organic framework (nMOF); Ferroptosis

Funding

  1. Hubei Provincial Natural Science Foundation [2020CFB152]
  2. Cultivating Project for Young Scholar at Hubei University of Medicine [2020QDJZR002, 2019QDJZR02]
  3. Innovative Research Program for Graduates of Hubei University of Medicine [YC2021016]
  4. National Training Program of Innovation and Entrepreneurship for Undergraduates [202110929010, 202113249001]
  5. Advantages Discipline Group (Medicine) Project in Higher Education of Hubei Province [2021-2025, 2022XKQY2]
  6. Undergraduate Innovation Program of Hubei University of Medicine [2022SY002, 2022SY003]

Ask authors/readers for more resources

This study presents an efficient chemodynamic therapy strategy based on dihydroartemisinin (DHA) as a substitute for H2O2 and recruiter of iron ions, leading to greatly increased reactive oxygen species generation for synergistic cancer therapy. Results demonstrate that DHA@MIL-101 nanoreactor significantly enhances intracellular iron ions and induces ferroptosis through ROS and LPO accumulation, ultimately causing DNA and mitochondria damage to induce apoptosis of malignant cells, with minimal systemic toxicity observed in vivo.
Background: Chemodynamic therapy (CDT) relying on intracellular iron ions and H2O2 is a promising therapeutic strategy due to its tumor selectivity, which is limited by the not enough metal ions or H2O2 supply of tumor microenvironment. Herein, we presented an efficient CDT strategy based on Chinese herbal monomer-dihydroartemisinin (DHA) as a substitute for the H2O2 and recruiter of iron ions to amplify greatly the reactive oxygen species (ROS) generation for synergetic CDT-ferroptosis therapy. Results: The DHA@MIL-101 nanoreactor was prepared and characterized firstly. This nanoreactor degraded under the acid tumor microenvironment, thereby releasing DHA and iron ions. Subsequent experiments demonstrated DHA@MIL-101 significantly increased intracellular iron ions through collapsed nanoreactor and recruitment effect of DHA, further generating ROS thereupon. Meanwhile, ROS production introduced ferroptosis by depleting glutathione (GSH), inactivating glutathione peroxidase 4 (GPX4), leading to lipid peroxide (LPO) accumulation. Furthermore, DHA also acted as an efficient ferroptosis molecular amplifier by direct inhibiting GPX4. The resulting ROS and LPO caused DNA and mitochondria damage to induce apoptosis of malignant cells. Finally, in vivo outcomes evidenced that DHA@MIL-101 nanoreactor exhibited prominent anti-cancer efficacy with minimal systemic toxicity. Conclusion: In summary, DHA@MIL-101 nanoreactor boosts CDT and ferroptosis for synergistic cancer therapy by molecular amplifier DHA. This work provides a novel and effective approach for synergistic CDT-ferroptosis with Chinese herbal monomer-DHA and Nanomedicine.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available